Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AMP 2026 Underscores Molecular Testing’s Role in Precision Medicine for Women’s Health

By LabMedica International staff writers
Posted on 16 Nov 2026

Advances in molecular diagnostics are creating new opportunities to improve the detection of sexually transmitted infections, identify antibiotic resistance, and assess cancer recurrence risk in women. More...

Researchers presenting at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo highlighted studies demonstrating how molecular testing and epigenetic profiling could support more precise diagnosis, treatment decisions, and individualized patient care.

The AMP 2026 Annual Meeting & Expo, held November 10–14 at the Seattle Convention Center in Seattle, Washington, brought together molecular pathology professionals to discuss developments in diagnostic testing and precision medicine. Among the research presented were two studies addressing antimicrobial resistance in sexually transmitted infections and molecular risk stratification in endometrial cancer.

Researchers at Unified Women's Healthcare and Alline (formerly Florida Woman Care) analyzed 121,966 vaginal swab specimens to investigate the prevalence of Mycoplasma genitalium, a sexually transmitted pathogen associated with cervicitis and pelvic inflammatory disease. Among 4,605 positive specimens with evaluable results, 41.5% showed resistance to macrolide antibiotics, highlighting the importance of resistance testing in guiding treatment decisions.

The researchers also implemented an automated reflex testing algorithm that achieved a median turnaround time of four days. The findings demonstrate the feasibility of incorporating resistance-guided testing into high-volume women's healthcare settings, supporting treatment approaches recommended by the U.S. Centers for Disease Control and Prevention (CDC).

In a separate oncology study, researchers at the University of California, San Francisco analyzed DNA methylation patterns in 219 tumors to investigate recurrence risk in patients with low-grade, limited-stage, copy number–low endometrioid adenocarcinoma, the most common type of endometrial cancer. The analysis identified methylation patterns strongly associated with recurrence risk, suggesting that epigenetic profiling could help distinguish patients whose tumors share similar conventional clinical and pathological characteristics.

The researchers also identified differences in molecular alterations across methylation-defined tumor groups, including enrichment of CTNNB1 and DICER1 mutations and copy number gains involving chromosome 1q. These findings suggest that DNA methylation profiling could provide additional information about tumor biology and potentially improve recurrence risk stratification beyond conventional pathological assessment.

Together, the studies presented at AMP 2026 highlight the expanding role of molecular diagnostics in women's healthcare, from identifying antibiotic resistance to improving cancer recurrence risk assessment. The findings demonstrate how integrating molecular and epigenetic information into diagnostic workflows could support more personalized treatment decisions and improve clinical management.

Related Links
Association for Molecular Pathology


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.